Shattuck Labs, Inc.
NASDAQ:STTKBiotechnology
+$0.11 today
- Market cap
- $455.24M
- Beta
- 1.09
- P/E (TTM)
- -10.9
- EPS (TTM)
- -$0.44
Volume 2.08M
Average 0.69M
STTK Depreciation & Amortization
Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.
Shattuck Labs, Inc.NASDAQ: STTK
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization declines year over year
Q1 FY2026 depreciation & amortization of $891K fell 4.8% year over year, behind the -3.9% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 1.7% from the prior quarter. Over 3 fiscal years it compounded at +6.3% a year.
Context
- Depreciation & amortization amounted to 368.8% of revenue in FY2025, up 301.9 pp from a year earlier.
- Depreciation & amortization increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -4.8% toward the trailing-twelve-month pace of -3.9%.
Sources:Income StatementText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the income statement
- Latest · FY2025
- 3.69M USD
- Year-over-year change
- -3.7%
- 4-year CAGR
- +27.9%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 3.69M | -3.7% |
| FY2024 | 2024-12-31 | 3.83M | -5.3% |
| FY2023 | 2023-12-31 | 4.04M | +31.5% |
| FY2022 | 2022-12-31 | 3.07M | +122.7% |
| FY2021 | 2021-12-31 | 1.38M | — |
Depreciation & Amortization vs competitors
How STTK compares with its peers on the latest reported figures
- Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -3.9% is the highest of 9, against a peer median of -56.4%.
- Depreciation & amortization amounts to 364.3% of revenue for STTK, versus a peer median of 4.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $42.96M USD | -7.4% | +30.8% | 11.3% | |
| LTM Mar 2026 | $10.64M USD | -6.8% | +3.6% | 4.7% | |
| LTM Mar 2026 | $3.64M USD | -3.9% | +6.3% | 364.3% | |
NBPNovaBridge Biosciences | LTM Sep 2025 | CN¥1.03M CNY | -95.7% | -55.8% | — |
| LTM Mar 2026 | $265K USD | -23.0% | -13.8% | — | |
| LTM Mar 2026 | $148K USD | -99.6% | -26.0% | 1.2% | |
| LTM Jun 2026 | $123K USD | -64.9% | -57.5% | — | |
| LTM Mar 2026 | $16.38K USD | -48.0% | +533.2% | — | |
| LTM Sep 2026 | $0 USD | -100.0% | — | — | |
| LTM Mar 2026 | $0 USD | — | — | — | |
| Peer median (excluding STTK) | — | -56.4% | -13.8% | 4.7% | |
Competitors are the stored peer set for STTK. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 30.02M | 652K | 1.66M | 5.72M | 1M |
| Cost of Revenue | 1.38M | 82.2M | 4.04M | 4.89M | 0 |
| Gross Profit | 28.64M | (81.55M) | (2.39M) | 827K | 1M |
| Gross Margin | 95.4% | -12507.2% | -143.9% | 14.5% | 100.0% |
| Research & Development | 56.56M | 82.9M | 74.31M | 67.21M | 35.27M |
| Selling, General & Admin | 18.72M | 19.68M | 19.3M | 19.08M | 17.24M |
| Operating Expenses | 73.91M | 21.78M | 89.57M | 81.39M | 52.51M |
| Depreciation & Amortization | 1.38M | 3.07M | 4.04M | 3.83M | 3.69M |
| EBITDA | (43.59M) | (98.87M) | (83.26M) | (71.58M) | (45.12M) |
| EBITDA Margin | -145.2% | -15164.4% | -5024.5% | -1251.2% | -4512.1% |
| Operating Income | (45.27M) | (103.33M) | (91.96M) | (80.57M) | (51.51M) |
| Operating Margin | -150.8% | -15848.0% | -5549.6% | -1408.3% | -5150.8% |
| Interest Income | 625K | 1.59M | 4.67M | 5.17M | 2.7M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 295K | 1.38M | 4.66M | 5.16M | 2.7M |
| Income Before Tax | (44.97M) | (101.95M) | (87.3M) | (75.41M) | (48.81M) |
| Pre-Tax Margin | -149.8% | -15635.7% | -5268.4% | -1318.1% | -4880.9% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (44.97M) | (101.95M) | (87.3M) | (75.41M) | (48.81M) |
| Net Margin | -149.8% | -15635.7% | -5268.4% | -1318.1% | -4880.9% |
| EPS (Basic) | (1.07) | (2.41) | (2.05) | (1.49) | (0.70) |
| EPS (Diluted) | (1.07) | (2.41) | (2.05) | (1.49) | (0.70) |
| Weighted Avg Shares | 42.03M | 42.38M | 42.6M | 50.76M | 69.58M |
| Weighted Avg Shares (Diluted) | 42.03M | 42.38M | 42.6M | 50.76M | 69.58M |
Shattuck Labs, Inc.
NASDAQ:STTK
Intrinsic Alpha fair value
Locked
Current Price
$4.47
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.